This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal
by Zacks Equity Research
Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).
Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl
by Zacks Equity Research
Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.
Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.
Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected to extend the company's cash runway into 2025.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Least-Hurt Biotech ETFs of the Last Week
by Sanghamitra Saha
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805
by Zacks Equity Research
Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
by Zacks Equity Research
Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
A Look at Pharma ETFs Post Q4 Earnings
by Sweta Killa
Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.
Company News for Feb 3, 2023
by Zacks Equity Research
Companies in The news Are: META, BMY, PH, CAH.
Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales
by Zacks Equity Research
Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.
Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge.
Goldilocks Econ Data Presides Over Pre-Market
by Mark Vickery
We haven't thrown around the term "Goldilocks" too much lately, but this morning, the shoe fits.
Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 6.43% and 2.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others
by Zacks Equity Research
Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.
Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock Down
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q4 earnings and sales. Its 2023 financial outlook falls short of expectations. Stock down in pre-market trading.
Qiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $72.45 in the latest trading session, marking a -0.74% move from the prior day.
Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to Decline
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.